{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T14:59:48Z","timestamp":1784818788913,"version":"3.55.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T00:00:00Z","timestamp":1737244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T00:00:00Z","timestamp":1737244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100018504","name":"Nipro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018504","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Performing hemodialysis without heparin is still challenging. The objective of the present work was to evaluate the impact on thrombogenicity of the hemodialysis circuit using synthetic membranes compared to the asymmetric cellulose triacetate\n                      <jats:bold>(<\/jats:bold>\n                      ATA) membrane.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Prospective, multicenter, randomized, crossover, open-label study. In each of the two phases of the study, six consecutive hemodialysis sessions were performed over two weeks, in which the patients were dialyzed with the dialyzer randomly\u00a0assigned (synthetic vs asymmetric cellulose triacetate membrane). During the six sessions of both phases, the heparin dose was progressively reduced from the full\u00a0usual heparin dose in the first session to zero heparin in\u00a0the sixth session. After each session, visual inspection of the venous chamber and dialyzer was performed, and a coagulation score was assigned. A micro- computed tomography (CT) scanning of some dialyzers was also executed\u00a0at Ghent University.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Comparison of the last completed sessions shows that there were significant differences depending on the dialyzer used: 60% of dialysis sessions with asymmetric cellulose triacetate could be completed without heparin versus 24% with synthetic membranes (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01). We also found differences in the number of sessions completed: 46% with the asymmetric cellulose triacetate membrane and 7% with the synthetic membrane (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001). The results obtained with\u00a0the micro-CT analysis\u00a0were also better with the asymmetric cellulose triacetate.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings strongly suggest that asymmetric cellulose triacetate membranes may be useful in situations in which dialysis should be\u00a0performed without heparin or with low-dose heparins.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trail registry<\/jats:title>\n                    <jats:p>NCT06505616.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s40620-024-02197-y","type":"journal-article","created":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T09:07:21Z","timestamp":1737277641000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["SOLFA study: a multicenter, open-label, prospective, randomized study to investigate the clotting propensity of asymmetric cellulose triacetate membrane compared to synthetic membranes in on\u00a0line HDF"],"prefix":"10.1093","clinical-trial-number":[{"clinical-trial-number":"nct06505616","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Marta","family":"Puerta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Teresa","family":"Jaldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Mart\u00ednez-Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1673-0353","authenticated-orcid":false,"given":"Francisco","family":"Maduell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Lancho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio Luis","family":"Garc\u00eda-Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6984-1743","authenticated-orcid":false,"given":"Sunny","family":"Eloot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7705-9228","authenticated-orcid":false,"given":"Patricia","family":"de Sequera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,19]]},"reference":[{"issue":"2","key":"2197_CR1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/sdi.12932","volume":"34","author":"SE Claudel","year":"2021","unstructured":"Claudel SE, Miles LA, Murea M (2021) Anticoagulation in hemodialysis: a narrative review. Semin Dial 34(2):103\u2013115. https:\/\/doi.org\/10.1111\/sdi.12932. (Epub 2020 Nov 1 PMID: 33135208)","journal-title":"Semin Dial"},{"issue":"Suppl 7","key":"2197_CR2","first-page":"63","volume":"17","author":"European Best Practice Guidelines Expert Group on Hemodialysis, European Renal Association","year":"2002","unstructured":"European Best Practice Guidelines Expert Group on Hemodialysis, European Renal Association (2002) Section V. Chronic intermittent haemodialysis and prevention of clotting in the extracorporal system. Nephrol Dial Transplant 17(Suppl 7):63\u201371","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"2197_CR3","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nrneph.2011.88","volume":"7","author":"A Davenport","year":"2011","unstructured":"Davenport A (2011) What are the anticoagulation options for intermittent hemodialysis? Nat Rev Nephrol 7(9):499\u2013508. https:\/\/doi.org\/10.1038\/nrneph.2011.88. (PMID: 21727925)","journal-title":"Nat Rev Nephrol"},{"key":"2197_CR4","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1038\/s41598-018-20898-w","volume":"8","author":"F Vanommeslaeghe","year":"2018","unstructured":"Vanommeslaeghe F, Van Biesen W, Dierick M et al (2018) Micro-computed tomography for the quantification of blocked fibers in hemodialyzers. Sci Rep 8:2677","journal-title":"Sci Rep"},{"issue":"2","key":"2197_CR5","first-page":"143","volume":"32","author":"JA Herrero-Calvo","year":"2012","unstructured":"Herrero-Calvo JA, Gonz\u00e1lez-Parra E, P\u00e9rez-Garc\u00eda R, Tornero-Molina F (2012) Grupo de Estudio Espa\u00f1ol Sobre Anticoagulaci\u00f3n en Hemodi\u00e1lisis. Spanish study of anticoagulation in haemodialysis. Nefrologia 32(2):143\u2013152","journal-title":"Nefrologia"},{"issue":"6","key":"2197_CR6","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1093\/ckj\/sfu114","volume":"7","author":"S Sahota","year":"2014","unstructured":"Sahota S, Rodby R (2014) Inpatient hemodialysis without anticoagulation in adults. Clin Kidney J 7(6):552\u2013556. https:\/\/doi.org\/10.1093\/ckj\/sfu114. (PMID: 25859371; PMCID: PMC4389149)","journal-title":"Clin Kidney J"},{"issue":"5","key":"2197_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0097187","volume":"9","author":"B Gu\u00e9ry","year":"2014","unstructured":"Gu\u00e9ry B, Alberti C, Servais A, Harrami E, Bererhi L, Zins B, Touam M, Joly D (2014) Hemodialysis without systemic anticoagulation: a prospective randomized trial to evaluate 3 strategies in patients at risk of bleeding. PLoS ONE 9(5):e97187. https:\/\/doi.org\/10.1371\/journal.pone.0097187. (PMID:24825343;PMCID:PMC4019548)","journal-title":"PLoS ONE"},{"issue":"1","key":"2197_CR8","doi-asserted-by":"publisher","first-page":"2302109","DOI":"10.1080\/0886022X.2024.2302109","volume":"46","author":"P Nakornchai","year":"2024","unstructured":"Nakornchai P, Jitraree A, Homjan MC, Laykhram T, Trakarnvanich T (2024) Comparison of citrate dialysate in pre- and post-dilution online hemodiafiltration: effect on clot formation and adequacy of dialysis in hemodialysis patients. Ren Fail 46(1):2302109. https:\/\/doi.org\/10.1080\/0886022X.2024.2302109. (Epub 2024 Jan 8. PMID: 38189095; PMCID: PMC10776067)","journal-title":"Ren Fail"},{"issue":"6","key":"2197_CR9","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1038\/ki.2014.225","volume":"86","author":"M Laville","year":"2014","unstructured":"Laville M, Dorval M, Fort Ros J, Fay R, Cridlig J, Nortier JL, Juillard L, D\u0119bska-\u015alizie\u0144 A, Fern\u00e1ndez Lorente L, Thibaudin D, Franssen C, Schulz M, Moureau F, Loughraieb N, Rossignol P (2014) Results of the HepZero study comparing heparin-grafted membrane and standard care show that heparin-grafted dialyzer is safe and easy to use for heparin-free dialysis. Kidney Int 86(6):1260\u20131267. https:\/\/doi.org\/10.1038\/ki.2014.225. (Epub 2014 Jul 9 PMID: 25007166)","journal-title":"Kidney Int"},{"issue":"2","key":"2197_CR10","doi-asserted-by":"publisher","first-page":"c107","DOI":"10.1159\/000158561","volume":"110","author":"K Bramham","year":"2008","unstructured":"Bramham K, Varrier M, Asgari E, Makanjuola D (2008) Comparison of Tinzaparin and unfractionated heparin as anticoagulation on haemodialysis: equal safety, efficacy and economical parity. Nephron Clin Pract 110(2):c107\u2013c113. https:\/\/doi.org\/10.1159\/000158561. (Epub 2008 Sep 30 PMID: 18824874)","journal-title":"Nephron Clin Pract"},{"key":"2197_CR11","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/j.1542-4758.2007.00166.x","volume":"11","author":"KG Fischer","year":"2007","unstructured":"Fischer KG (2007) Essentials of anticoagulation in hemodialysis. Hemodial Int 11:178\u2013189","journal-title":"Hemodial Int"},{"issue":"3","key":"2197_CR12","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1681\/ASN.2012080875","volume":"24","author":"F Maduell","year":"2013","unstructured":"Maduell F, Moreso F, Pons M, Ramos R, Mora-Maci\u00e0 J, Carreras J, Soler J, Torres F, Campistol JM, Martinez-Castelao A, ESHOL Study Group (2013) High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol 24(3):487\u2013497. https:\/\/doi.org\/10.1681\/ASN.2012080875. (Epub 2013 Feb 14. Erratum in: J Am Soc Nephrol. 2014 May;25(5):1130. PMID: 23411788; PMCID: PMC3582206)","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"2197_CR13","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1056\/NEJMoa2304820","volume":"389","author":"PJ Blankestijn","year":"2023","unstructured":"Blankestijn PJ, Vernooij RWM, Hockham C, Strippoli GFM, Canaud B, Hegbrant J, Barth C, Covic A, Cromm K, Cucui A, Davenport A, Rose M, T\u00f6r\u00f6k M, Woodward M, Bots ML, CONVINCE Scientific Committee Investigators (2023) Effect of hemodiafiltration or hemodialysis on mortality in kidney failure. N Engl J Med 389(8):700\u2013709. https:\/\/doi.org\/10.1056\/NEJMoa2304820. (Epub 2023 Jun 16. PMID: 37326323)","journal-title":"N Engl J Med"},{"issue":"1","key":"2197_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1542-4758.2009.00336.x","volume":"13","author":"KI Sombolos","year":"2009","unstructured":"Sombolos KI, Fragia TK, Gionanlis LC, Veneti PE, Bamichas GI, Fragidis SK, Georgoulis IE, Natse TA (2009) The anticoagulant activity of enoxaparin sodium during on-line hemodiafiltration and conventional hemodialysis. Hemodial Int 13(1):43\u201347. https:\/\/doi.org\/10.1111\/j.1542-4758.2009.00336.x. (Erratum.In:HemodialInt.2009Apr;13(2):235.Dosageerrorinpublishedabstract;MEDLINE\/PubMedabstractcorrected PMID: 19210277)","journal-title":"Hemodial Int"},{"issue":"4","key":"2197_CR15","doi-asserted-by":"publisher","first-page":"844","DOI":"10.3390\/biomedicines10040844","volume":"10","author":"M Bonomini","year":"2022","unstructured":"Bonomini M, Piscitani L, Di Liberato L, Sirolli V (2022) Biocompatibility of surface-modified membranes for chronic hemodialysis therapy. Biomedicines 10(4):844. https:\/\/doi.org\/10.3390\/biomedicines10040844. (PMID:35453594;PMCID:PMC9025662)","journal-title":"Biomedicines"},{"issue":"5","key":"2197_CR16","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1159\/000501035","volume":"44","author":"J Martin-Navarro","year":"2019","unstructured":"Martin-Navarro J, Esteras R, Castillo E, Carriazo S, Fern\u00e1ndez-Prado R, Gracia-Iguacel C, Mas Fontao S, Ort\u00edz A, Gonz\u00e1lez-Parra E (2019) Reactions to Synthetic Membranes Dialyzers: Is there an Increase in Incidence? Kidney Blood Press Res 44(5):907\u2013914. https:\/\/doi.org\/10.1159\/000501035. (Epub 2019 Sep 10 PMID: 31505506)","journal-title":"Kidney Blood Press Res"},{"issue":"3","key":"2197_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.nefro.2017.11.015","volume":"38","author":"M Albalate Ram\u00f3n","year":"2018","unstructured":"Albalate Ram\u00f3n M, Mart\u00ednez Miguel P, Bohorquez L, de Sequera P, Bouarich H, P\u00e9rez-Garc\u00eda R, Rodr\u00edguez Puyol D, Barril G, S\u00e1nchez Tomero JA, Giorgi M, Ramirez Chamond MR (2018) Asymmetric cellulose triacetate is a safe and effective alternative for online haemodiafiltration. Nefrologia (Engl Ed) 38(3):315\u2013320. https:\/\/doi.org\/10.1016\/j.nefro.2017.11.015. (Epub 2018 Feb 15. PMID: 29454540)","journal-title":"Nefrologia (Engl Ed)"},{"issue":"8","key":"2197_CR18","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1093\/ckj\/sfaa228","volume":"14","author":"I Vandenbosch","year":"2020","unstructured":"Vandenbosch I, Dejongh S, Claes K, Bammens B, De Vusser K, Van Craenenbroeck A, Kuypers D, Evenepoel P, Meijers B (2020) Strategies for asymmetrical triacetate dialyzer heparin-free effective haemodialysis: the SAFE study. Clin Kidney J 14(8):1901\u20131907. https:\/\/doi.org\/10.1093\/ckj\/sfaa228. (PMID:34345413;PMCID:PMC8323132)","journal-title":"Clin Kidney J"},{"issue":"7","key":"2197_CR19","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1093\/ckj\/sfaa219","volume":"14","author":"F Vanommeslaeghe","year":"2020","unstructured":"Vanommeslaeghe F, Josipovic I, Boone M, van der Tol A, Dhondt A, Van Biesen W, Eloot S (2020) How biocompatible haemodialyzers can conquer the need for systemic anticoagulation even in post-dilution haemodiafiltration: a cross-over study. Clin Kidney J 14(7):1752\u20131759. https:\/\/doi.org\/10.1093\/ckj\/sfaa219. (PMID:34548919;PMCID:PMC8447252)","journal-title":"Clin Kidney J"},{"key":"2197_CR20","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.nefro.2018.11.002","volume":"4","author":"OP de Sequera","year":"2019","unstructured":"de Sequera OP, P\u00e9rez Garc\u00eda R, Molina Nu\u00f1ez M, Mu\u00f1oz Gonz\u00e1lez RI, \u00c1lvarez Fern\u00e1ndez G, M\u00e9rida Herrero E, Camba Caride MJ, Bl\u00e1zquez Collado LA, Alcaide Lara MP, Echarri Carrillo R, en representaci\u00f3n del grupo del estudio ABC-treat; Grupo del estudio ABC-treat (2019) Prospective randomised multicentre study to demonstrate the benefits of haemodialysis without acetate (with citrate): ABC-treat Study Acute effect of citrate. Nefrologia (Engl Ed). 4:424\u2013433. https:\/\/doi.org\/10.1016\/j.nefro.2018.11.002. (Epub 2019 Jan 24. PMID: 30686542)","journal-title":"Nefrologia (Engl Ed)."},{"issue":"1","key":"2197_CR21","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1038\/s41598-018-20898-w","volume":"8","author":"F Vanommeslaeghe","year":"2018","unstructured":"Vanommeslaeghe F, Van Biesen W, Dierick M, Boone M, Dhondt A, Eloot S (2018) Micro-computed tomography for the quantification of blocked fibers in hemodialyzers. Sci Rep 8(1):2677. https:\/\/doi.org\/10.1038\/s41598-018-20898-w. (PMID:29422614;PMCID:PMC5805764)","journal-title":"Sci Rep"},{"issue":"suppl7","key":"2197_CR22","first-page":"63","volume":"17","author":"European Best Practice Guidelines Expert Groupon Hemodialyis. European Renal Association. Section V","year":"2002","unstructured":"European Best Practice Guidelines Expert Groupon Hemodialyis. European Renal Association. Section V (2002) Chronic intermittent haemodialysis and prevention of clotting in the extracorporeal system. Nephrol Dial Transplant 17(suppl7):63\u201371","journal-title":"Nephrol Dial Transplant"},{"key":"2197_CR23","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1186\/s12882-019-1527-3","volume":"20","author":"D Ashby","year":"2019","unstructured":"Ashby D, Borman N, Burton J et al (2019) Renal association clinical practice guideline on haemodialysis. BMC Nephrol 20:379","journal-title":"BMC Nephrol"},{"key":"2197_CR24","unstructured":"BC van Jaarsveld. Antistolling bij hemodialyse. Nederlandse Federatie Voor Nefrologie. 2012. Accessed 2 September 2024. https:\/\/www.nefro.nl\/richtlijnen\/antistolling-bij-hemodialyse-2012."},{"issue":"6","key":"2197_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2023.151483","volume":"43","author":"FV Janssens","year":"2023","unstructured":"Janssens FV, Meijers B, Fran\u00e7ois K (2023) Avoiding systemic heparinization during hemodialysis: how the dialysis setup might help. Semin Nephrol 43(6):151483. https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151483. (Epub 2024 Jan 13. PMID: 38220473)","journal-title":"Semin Nephrol"},{"issue":"1","key":"2197_CR26","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/ckj\/sfz163","volume":"14","author":"F Vanommeslaeghe","year":"2019","unstructured":"Vanommeslaeghe F, Josipovic I, Boone M, Dhondt A, Van Biesen W, Eloot S (2019) A randomized cross-over study with objective quantification of the performance of an asymmetric triacetate and a polysulfone dialysis membrane using different anticoagulation strategies. Clin Kidney J 14(1):398\u2013407. https:\/\/doi.org\/10.1093\/ckj\/sfz163. (Erratum.In:ClinKidneyJ.2020Sep04;14(1):463-464.PMID:33564444;PMCID:PMC7857793)","journal-title":"Clin Kidney J"},{"key":"2197_CR27","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000451044","volume":"189","author":"T Sunohara","year":"2017","unstructured":"Sunohara T, Masuda T (2017) Fundamental characteristics of the newly developed ATA\u2122 membrane dialyzer. Contrib Nephrol 189:215\u2013221. https:\/\/doi.org\/10.1159\/000451044. (Epub 2016 Dec 12 PMID: 27951571)","journal-title":"Contrib Nephrol"},{"key":"2197_CR28","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1159\/000329055","volume":"173","author":"T Sunohara","year":"2011","unstructured":"Sunohara T, Masuda T (2011) Cellulose triacetate as a high-performance membrane. Contrib Nephrol 173:156\u2013163. https:\/\/doi.org\/10.1159\/000329055. (Epub 2011 Aug 8 PMID: 21865788)","journal-title":"Contrib Nephrol"},{"key":"2197_CR29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s41100-018-0171-x","volume":"4","author":"K Togo","year":"2018","unstructured":"Togo K, Yamamoto M, Imai M et al (2018) Comparison of biocompatibility in cellulose triacetate dialysis membranes with homogeneous and asymmetric structures. Ren Replace Ther 4:29. https:\/\/doi.org\/10.1186\/s41100-018-0171-x","journal-title":"Ren Replace Ther"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-024-02197-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-024-02197-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-024-02197-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:54:11Z","timestamp":1777564451000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/38\/2\/697\/8307210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,19]]},"references-count":29,"alternative-id":["2197"],"URL":"https:\/\/doi.org\/10.1007\/s40620-024-02197-y","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,19]]},"assertion":[{"value":"23 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"P.S. reports honorarium for conferences, consulting fees and advisory boards from Amgen, Astellas, Astra Zeneca, Baxter, Braun, Fresenius, Nipro, Vifor-Pharma. P.M. reports honorarium for conferences and consulting fee from Nipro. F.M. has received consultancy and lecture fees from Baxter, Fresenius Medical Care, Medtronic, Nipro, Toray, and Vifor. The remaining authors declare no potential conflicts of interest related to the contents of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the local Ethics Committee, and it was conducted according to the principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients who participated in the study provided signed informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}